Endovascular treatment for acute basilar artery occlusion: A multicenter randomized controlled trial (ATTENTION)

Wrong goal.

Still a ways to go, mRS score should be zero(No symptoms) for all treated. Until we get researchers to shoot for the correct goal, 100% recovery, all stroke survivors will be screwed now and forever.

Endovascular treatment for acute basilar artery occlusion: A multicenter randomized controlled trial (ATTENTION)

Show all authors

Chunrong Tao*, Rui Li*, Yuyou Zhu, ...

First Published February 22, 2022 Research Article Find in PubMed 

https://doi.org/10.1177/17474930221077164

Article information

Abstract

Background and hypothesis:

Recently, two multicenter randomized controlled trials (RCT) failed to show a significantly beneficial effect of endovascular treatment (EVT) in patients with acute basilar artery occlusion (BAO). However, both trials suffered from equipoise issues which may have hindered the validity of the trial results. Therefore, additional RCT studies are needed to explore the potential benefit of EVT in patients presenting with BAO.

Study design:

ATTENTION is an investigator-initiated, multicenter, prospective, randomized, controlled clinical trial with open-label treatment and blinded outcome assessment (PROBE) of EVT versus best medical management (BMM). The primary effect parameter is a modified Rankin Score of 0–3 at day 90.

Discussion:

ATTENTION will provide evidence for the efficacy and safety of EVT in stroke patients within 12 h after BAO.

Trial registration:

ClinicalTrials.gov NCT04751708

Keywords

Basilar artery occlusion, ischemic stroke, endovascular treatment, randomized trial

Access Options